Biogen MS Drug Patent Survives Mylan's PTAB Challenge
The Patent Trial and Appeal Board has refused to invalidate a Biogen patent covering the blockbuster multiple sclerosis drug Tecfidera, following a challenge from Mylan....To view the full article, register now.
Already a subscriber? Click here to view full article